


↑
CTRL

↑
HH-Ab TREATED


↑
CTRL

FIG. 1A




5 WEEKS OLD MICE


FIG. 1B



CTRL Ab
FIG. 1C



ANTI-HEDGEHOG Ab
FIG. 1D



CTRL E18.5



HH-Ab TREATED E18.5

FIG. 1E

FIG. 1F



FIG. 1G



FIG. 1H



HH-Ab TREATED AT d17

FIG. 1J



CTRL d17

FIG. 1I




FIG. 2



HH-Ab TREATMENT AFTER BIRTH
AND CONTINUED TO d10

FIG. 3B



CTRL AT d2

FIG. 3A

CTRL MICE 8/11





FIG. 4A

5 WEEKS OLD



CONTINUOUS-TREATED MICE

SUSPENDED MICE

CTRL MICE

FIG. 4B

CONSENSUS SEQUENCE OF N-terminal fragments

SEQ ID NO. 4

1

CGPGR^{x1} x2 x3 x4 x5

RR_{x6} x7 x8 K_{x9}L_{x10}P

$$L_{X11} YKQF_{X12} P_{X13} V$$

x14 ERTLGR

40

9/11

x15EGKx16 x17Rx18SE

REF_{x19}L_{x20}PNYN

PDIIFKDEEN

x21GADRLMT_{x22R}

CK_{x23} X24 X25 NSLAI

x26 VMN_{x27}WPGVK

L R V T E G W D E D

120
GHH_{x28} x29 x30SLHY

EGRVDITTS

DRDR_{x31}KYG_{x32}L

ARLAVEAGED

160
WVYYES_{X33} X34^HX25

H_{x36SVK}x37 x38 x39S_{x40}

AA_{x41} x42^{GG}

176

FIG. 5A

Where:

X1 is either V or G;
X2 is either V, F or P;
X3 is either G or V;
X4 is either S or G;
X5 is either R or K;
X6 is either P, H or Y;
X7 is either P or A;
X8 is either R or K;
X9 is any amino acid;
X10 is either V or T;
X11 is either A or L;
X12 is either S, I or V;
X13 is either N or G;
X14 is either P or A;
X15 is either Y or A;
X16 is either I or V;
X17 is either A or S;
X18 is either S, N or G;
X19 is either E or D;
X20 is either T or V;

FIG. 5B

X21 is either T or S;
 X22 is either Q or E;
 X23 is either D or E;
 X24 is either R or K;
 X25 is either L or V;
 X26 is either S or A;
 X27 is either Q or M;
 X28 is either S or A;
 X29 is either E or Q;
 X30 is either E or D;
 X31 is either N or S;
 X32 is either N or M;
 X33 is either K or R;
 X34 is either A or N;
 X35 is either V or I;
 X36 is either C or V;
 X37 is either S or A;
 X38 is either E or D;
 X39 is either H or N;
 X40 is either A, V or L;
 X41 is either K or R; and
 X42 is either T, S or A.

FIG. 5C